BNiQ Network Graph
Displaying all people that are connected to 2 or more organisations. Hover over a node to display a link to the BNiQ page for that person or organisation.
Showing 11 people. Position shown in italic is their previous role in the same organisation.
Most Senior WA Executive.
|Non-Executive Director, Chair 2015-2017||2015|
|Global Head of Manufacturing & Operations||2015|
|Chief Executive, Managing Director||2015|
Non-Executive Director (2005 to 2007)
|Chief Financial Officer, Company Secretary||2015|
|Chief Medical Officer||2015|
|Director, Sales & Marketing||2016|
|Vice President, Regulatory Affairs & Quality||2015|
|Name||Position||Year Started||Year Ended|
|Martin Rogers||Non-Executive Director (Chair 2013-2014)||2013||2016|
|Bret Mattes||Non-Executive Chairman||2011||2013|
|Simon O'Loughlin||Non-Executive Director||2012||2013|
|Neville Bassett||Non-Executive Director||2010||2012|
|Kyle Haynes||Executive Director||0||2012|
|Harry Karelis||Non-Executive Chairman||0||2011|
|David McAuliffe||Executive Director||2005||2010|
|Mark Treherne||Executive Chairman||2005||2010|
|Morgan Barron||Company Secretary||2008||2010|
|Chriss Moyses||Non-Executive Director||0||2009|
|Iain Chessell||Chief Executive Officer||0||2009|
|Narelle Warren||Company Secretary||2007||2009|
|Tony Evans||Non-Executive Director||2007||2009|
|John Hannaford||Non-Executive Director||2005||2009|
|Tony King||Non-Executive Director||2005||2007|
|Mark Bianchini||Company Secretary||0||2007|
|Narelle Lloyd||Company Secretary||2007|
|Alistair Dixon||Executive Director||2005||2006|
BiographyOncosil Medical, a neuroscience drug development company, operates in the life science sector in the United Kingdom and Australia. It engages in the development of compounds for the treatment of neuropathic pain. The company’s products under development include NSL-101, a natural product formulation for the treatment of pain, which has completed two Phase II clinical trials; and NSL-043, an oral product for neuropathic pain, which has completed two Phase I clinical trials. It has collaboration agreement with Sosei Corporation for developing NSL-043.
Biography last updated 04 Jun 2018